Loading
HER2/EGFR in Cancer Research / Advanced Breast Cancer Therapies · Journal article
P a Herzen Journal of Oncology · August 10, 2026
A consensus or society position rather than new primary data.
This narrative review consolidates evidence from Phase 3 RCTs (MONALEESA-2, MONALEESA-3, CompLEEment-1) and FDA pooled analyses demonstrating that ribociclib-based combination endocrine therapy reduces risks of disease recurrence and death compared to endocrine monotherapy in elderly and frail patients with HR-positive, HER2-negative breast cancer. The review synthesizes safety data, immune modulation findings from the phase 4 RibOB trial, cardiovascular toxicity patterns, and practical drug–drug interaction management, providing a clinical framework for oncologists managing this population.
Narrative review synthesizing Phase 3 RCTs, Phase 4 trial, real-world practice studies, and FDA pooled analyses. Elderly and frail patients with advanced HR-positive, HER2-negative breast cancer, including subgroups aged ≥70 and ≥75 years from PALOMA-2, MONALEESA-2, MONALEESA-3, CompLEEment-1, MONARCH-3, and phase 4 RibOB trial. Intervention: Combination endocrine therapy with ribociclib (CDK4/6 inhibitor). Compared with: Endocrine monotherapy.
Phase 3 RCTs (MONALEESA-2, MONALEESA-3, CompLEEment-1) consistently demonstrated significant advantage of ribociclib combination endocrine therapy over endocrine monotherapy in reducing risks of disease recurrence and death in older patients and those with ECOG performance status ≥2 Phase 4 RibOB trial showed three months of combination endocrine therapy with ribociclib modulates immune system in elderly patients, expanding naïve T and B cell populations while reducing memory cell compartment FDA pooled analyses from PALOMA-2, MONALEESA-2, and MONARCH-3 evaluated efficacy and safety in adults aged ≥70 years and ≥75 years
Cardiovascular toxicity described only as 'reported to FDA Adverse Event Reporting System' without quantitative summary Review does not provide sample sizes or detailed efficacy/safety numbers for the elderly and frail subgroups
Oncologists can use this synthesis to support combination ribociclib-endocrine therapy decisions in elderly and frail patients, including those with poor performance status, and to systematically manage safety monitoring, immune effects, and drug interactions in routine practice.
A narrative review synthesizing Phase 3 RCT evidence, real-world studies, and FDA analyses to provide practical clinical recommendations on ribociclib use in elderly and frail patients, rather than reporting a new primary trial result.
As stated by the source record.
Quoted from the source exactly as published.
Oncologists can use this synthesis to support combination ribociclib-endocrine therapy decisions in elderly and frail patients, including those with poor performance status, and to systematically manage safety monitoring, immune effects, and drug interactions in routine practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This review presents the findings of the most consequential large-scale randomized controlled trials and real-world practice studies on combination endocrine therapy with ribociclib in elderly patients with advanced HR-positive, HER2-negative breast cancer. Phase 3 and 3b randomized clinical trials (MONALEESA-2, MONALEESA-3, and CompLEEment-1) have consistently demonstrated that endocrine therapy combined with ribociclib confers a significant advantage over endocrine monotherapy in reducing the risks of disease recurrence and death—not only in older patients overall, but also in frail individuals with an ECOG performance status of 2 or higher. Particular emphasis is placed on the safety profile of ribociclib, with special attention to adverse events of special interest that demand enhanced monitoring throughout treatment. The phase 4 RibOB clinical trial has, for the first time, shown that three months of combination endocrine therapy with ribociclib modulates the immune system in elderly patients, potentially correcting age-related immunodeficiency by expanding the population of naïve T and B cells while reducing the memory cell compartment. A dedicated section examines two independent FDA pooled analyses evaluating the efficacy and safety of combination endocrine therapy in older adults (aged ≥70 years and ≥75 years) enrolled in three major randomized trials (PALOMA-2, MONALEESA-2, and MONARCH-3). This is complemented by a detailed review of cardiovascular toxicity associated with CDK4/6 inhibitors, as reported to the FDA Adverse Event Reporting System in routine clinical practice. The review also addresses clinically relevant drug–drug interactions that warrant careful consideration during CDK4/6 inhibitor therapy, and provides a practical clinical algorithm for managing concomitant use of CYP3A4 inhibitors or inducers when such co-administration becomes necessary.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.